Atopic Dermatitis

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

Let us know what content you want to see from RAD.

Results of a new study indicate that baricitinib offers a potential therapeutic option with a favorable benefit-risk profile for pediatric patients with moderate-to-severe AD.

Physical activity and exercise may lead to improved mental health but exacerbate skin conditions.

ASLAN Pharmaceuticals will present 2 late-breaking abstracts and 2 additional abstracts.

When compared to a vehicle control cream, researchers said delgocitinib cream proved more efficacious.

Click here to answer this week's poll.